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Abstract: Background: Conclusive information regarding the influence of race on survival among
neuroblastoma patients is limited. Our objective is to investigate the association between race and
cause-specific survival in pediatric patients diagnosed with neuroblastoma in the US between 1973
and 2015. Methods: This was a retrospective cohort study using the Surveillance, Epidemiology,
and End Result (SEER) database. Patients aged 17 and younger of black, white, or Asian Pacific
Islander (API) race diagnosed with neuroblastoma from 1973–2015 were included (n = 2,119).
The outcome variable was time from diagnosis to death. Covariates included age, gender, ethnicity,
stage, tumor site, and year of diagnosis. Cox proportional hazard models were used to calculate
hazard ratios and 95% confidence intervals. Results: There were no statistically significant differences
in the hazard of survival for blacks (HR 0.93; 95% confidence interval (CI) 0.74–1.16) or API (HR 1.02;
95% CI 0.76–1.37) compared with whites. However, patients diagnosed between 2000–2004 (HR 0.46;
95% CI 0.36–0.59) and 2005–2015 (HR 0.33; 95% CI 0.26–0.41) had decreased hazards of death when
compared to patients treated during 1973 to 1999. Conclusions: No association between race and
survival time was found. However, survival improved among all patients treated during 2000–2004
and 2005–2015 compared with those treated before the year 2000, leading to a narrowing of the racial
disparity based on survival.
Keywords: neuroblastoma; neoplasms; child; ethnic groups; epidemiology; mortality; population cohort

1. Introduction
Among the pediatric population, cancer is the leading cause of disease-related death [1].
Neuroblastoma is the most common childhood cancer diagnosed during the first year of life, and the
third most commonly diagnosed childhood cancer overall. Overall survival rates for children with
neuroblastoma have seen an upward trend [2]. Yet, the prognosis for neuroblastoma patients depends
on various factors such as age of the child when diagnosed, and the stage, the molecular, and cytological
characteristics of the tumor. Moroz et al. revealed that even though adverse influence of increasing
age-at-diagnosis has declined, it remains a powerful indicator of unfavorable prognosis [3].
Racial disparities in cancer survival have been extensively researched for hematological
malignancies, but less so for solid tumors, including neuroblastoma [4]. Whites have a higher
incidence of neuroblastoma than blacks and other races [5,6]. Possible reasons for such disparities in
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incidence of neuroblastoma include differences in socioeconomic status, delays in diagnosis because of
inadequate access to care, lack of cancer knowledge on the part of patients, risky health behaviors,
and differing disease biology [7].
Despite racial differences reported in the incidence of neuroblastoma, there is not much research on
how race influences survival among children with neuroblastoma [8–14]. Results in regard differences
in survival between white and black patients have been inconsistent [8,11–14]. Whereas some of the
previous studies using SEER data revealed a reduced survival in Back patients [10,11], others did
not coincide [9,12,14]. A study of 3539 children diagnosed with neuroblastoma and participating
in the Children’s Oncology Group neuroblastoma biology protocol between 2001 and 2009 showed
that compared to whites, blacks had a 1.4-fold risk of death due to neuroblastoma, while Asians and
Native Americans had a 1.6 and a 3-fold increased risk, respectively. While blacks and whites were
the most commonly included in studies, studies that also assess Native Americans and Asians [8,9],
Hispanics [8,9,12], American Indians and Native Pacific Islanders [9,12] survival in neuroblastoma
patients are scarce [8–10,12].
The objective of the present study was to determine if there is an association between race and
5-year cause-specific survival in pediatric patients diagnosed with neuroblastoma in the United States
between 1973 and 2015.
2. Materials and Methods
2.1. Study Design and Population
A secondary analysis of data from the National Cancer Institute’s Surveillance, Epidemiology,
and End Result (SEER) Database was performed. Briefly, SEER is a surveillance system that collects
and publishes cancer incidence and survival data from population-based cancer registries throughout
the US. Registries comprise 34% of the US population and originate from 19 geographical areas [15].
For this study, children aged 17 years or younger diagnosed with a first-time diagnosis of
neuroblastoma (ICD-O-3 9500/3) from 1973 to 2015 were included. After exclusion of participants
missing information on survival, and participants for which diagnosis was done at autopsy,
and duplicate information, the final sample size was 2119.
2.2. Main Variables
The primary outcome was cause-specific survival, defined as the time in months from diagnosis
to death due to neuroblastoma, which was recorded up to 60 months. This was calculated using the
SEER cause-specific death classification (dead, alive/dead of other cause) and survival time (in months).
The independent variable of interest was race categorized as white, black, or Asian Pacific Islanders (API).
Other variables assessed included sex (male/female), ethnicity (Hispanic, Non-Hispanic), participant’s age
(categorized into <1 year, 1 to 4 years, and 5 to 17 years), year of diagnosis, cancer stage (localized,
regional, distant, unstaged/unknown), and primary neuroblastoma site (adrenal or non-adrenal sites)
according to ICD-0-3 codes available at the SEER database. Adrenal site was considered if codes ranged
from C740–C749. Non-adrenal sites category included neuroblastoma of the mediastinum (codes C381
to C383), autonomic nervous system (codes C470-C479), retroperitoneum (code C480), connective tissue
(codes C490 to C499), and central nervous system (codes C700 to C729). These age group categorization
was based on survival prognosis previously described [3]. Pinto et al. showed that survival rates were
determined to be significantly different according to diagnostic era with better outcome observed for
patients diagnosed after 2000, when consolidation with HDT and stem-cell rescue was routinely included
in the treatment plan for high-risk patients [16]. Only 6% (64 of 1015) of the patients diagnosed between
2000 and 2004 and 30% (445 of 1484) of those diagnosed between 2005 and 2010 received immunotherapy
and cytokines plus isotretinoin after consolidation. Postconsolidation treatment with immunotherapy and
cytokines plus isotretinoin is now considered part of standard-of-care treatment. Therefore, the categories
of year of diagnosis, were the intervals of 1979 to 1999, 2000 to 2004, and 2005 to 2015 as to coincide
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with changes in treatment protocol for neuroblastoma implemented in 2000 and 2005 that could impact
patient’s outcomes [16].
2.3. Analysis
The data were exported from SEER and analyzed with Stata SE version 14 (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, Texas, TX: StataCorp LP, USA). All data accessed
from SEER were de-identified (fully anonymized) according to the Health Insurance Portability
and Accountability Act. Stata software version 15 was used for all analyses [17]. We performed
descriptive statistics to assess the frequency distributions of the variables and patterns of missing data.
Bivariate analyses were conducted to compare the distribution of potential confounders by race.
Chi squared tests were used to assess statistical significance. Kaplan Meier curves were generated by
selected independent variables (by race and year of diagnosis) and log-rank tests were performed to
assess for statistical differences between the survival curves across the different independent variables.
Cox proportional hazards regression models were used to calculate the unadjusted and adjusted hazard
ratios with their corresponding 95% confidence intervals. Statistical significance was considered for
p-value of less than or equal to 0.05 (two tailed tests).
2.4. Ethical Considerations
This study was reviewed by the Florida International University (FIU) Office of Research Integrity
and determined to be Not Human Subject Research. As a result, the study did not require submission
to and approval of the FIU Institutional Review Board (IRB). The privacy of all participants was
maintained as all information utilized was secondary de-identified data obtained from SEER.
3. Results
Table 1 describes the demographics and clinical characteristics for patients with neuroblastoma
in the SEER registry from 1973–2015. When compared with whites and API patients, a significantly
higher proportion of black patients were Non-Hispanic (89% vs. 95.8% vs. 97.5%) and were diagnosed
with neuroblastoma at 1–4 years old (55.8%). A lower proportion of black patients were <1 year of age
at presentation compared with white and API. Also, a higher proportion of API patients had adrenal
disease compared with white and black patients. A higher proportion of API patients, when compared
to whites and blacks, had a distant stage at diagnosis (44.9% vs. 40.6% vs. 37.2%) and were diagnosed
between 2005 and 2015 (40.6% vs. 27.3% vs. 34.7%). More API had adrenal neuroblastomas than
whites and blacks, respectively (53.9% vs. 40.6% vs. 40%).
Figure 1 displays the Kaplan Meier adjusted survival curves according to race from 1973–2015.
Survival was statistically significantly different among the year of diagnosis. Analysis of the data did
not show statistically significant differences in survival between the three racial groups (log rank test
p-value 0.11).
Table 2 shows the unadjusted and adjusted hazard ratios for 5-year cause-specific survival in
the study sample. The final adjusted model included age, gender, ethnicity, stage, site, and year of
diagnosis. These covariates were identified as being clinically relevant and were sued in previous
studies as well [8–14]. In addition, they were unequally distributed according to the race (Table 1) and
the survival. After adjusting for these covariates, there were no statistically significant differences in
the hazard of survival for blacks (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.74–1.16) or API
(HR 1.02; 95% CI 0.76–1.37) when compared with whites. Results were also not significant for female
(HR 0.89; 95% CI 0.76–1.04), Hispanic ethnicity (HR 1.00; 95% CI 0.75–1.34), and adrenal primary
tumor site (HR 1.16; 95% CI 0.99–1.36). Patients 1–4 and 5–17 years-old had, respectively, a 5.92-fold
(95% CI 4.64–7.56) and 7.29-fold (95% CI 5.51–9.66) greater hazard of death when compared with
those <1 years-old. Lastly, distant stage had the higher death hazard compared to the localized stage
(HR 9.03; CI 4.94–16.49). Lastly, patients diagnosed between 2000–2004 (HR 0.46; 95% CI 0.36–0.59)
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and 2005–2015 (HR 0.33; 95% CI 0.26–0.41) had significantly lower hazards of death when compared
with patients diagnosed from 1973 to 1999.
Table 1. Demographic and clinical characteristics, by race, of pediatric patients in the SEER registry
diagnosed with neuroblastoma, 1973–2015.
Characteristics

White (n = 1680)
%
(n)

Black (n = 274)
%
(n)

API a (n = 165)
%
(n)

Age (years)
<1
1–4
5–17

43.1
46.5
10.4

−724
−781
−175

29.6
55.8
14.6

−81
−153
−40

43.6
45.5
10.9

−72
−75
−18

Gender
Male
Female

54.6
45.4

−917
−763

52.6
47.5

−144
−130

57
43

−94
−71

0.001

0.661

<0.001

Ethnicity
Int. J. Environ. Res. Public Health 2020, 17, x
Hispanic
11.3
−190
Non-Hispanic
89
−1490
Regional
18.3
−308

2.55
97.5
17.2

−7
4.2
−267
95.8
−47
14
−23

Distant
40.6
Stage
LocalizedUnstaged/Unknown
10.7 30.4
Site
Regional
18.3
Distant Adrenal
40.6 40.6
Non-Adrenal
Unstaged/Unknown
30.4 59.4

−682

37.2

−510
−180
−308
−682
−682
−998
−510

36
9.5
17.2
40.5
37.2
59.5
36

−102
44.9
−74
−99
−26 31 10.3−51

59.5
−999
40.6 13.3 −682
−223
59.4 27.3 −998
−458

52.6
40.5
12.8
59.5
34.7

Year

Site

1973–1999
Adrenal 2000–2004
Non-Adrenal
2005–2015

Year

p-Value
(n)

a

−7
−158

0.415

−111
−102 53.9 44.9−89
−163
−99 46.1 31−76

−17
0.004
−23
−74
−51

−144
46.7
−77
−111 12.7 53.9−21
−35
−163 40.6 46.1−67
−95

−89
−76

−47

14
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0.001

0.004

Asian Pacific Islander.

0.001
1973–1999
59.5
−999
52.6
−144
46.7
−77
Figure 1 displays the Kaplan Meier adjusted survival curves according to race from 1973–2015.
2000–2004
13.3
−223
12.8
−35
12.7
−21
Survival was statistically significantly different among the year of diagnosis. Analysis of the data did
2005–2015
27.3
−458
34.7
−95
40.6
−67

not show statistically significant differences in survival between the three racial groups (log rank test
a Asian Pacific Islander.
p-value 0.11).

Figure 1. Adjusted survival curves according to race for patients in the SEER database diagnosed with

Figure 1. Adjusted survival curves according to race for patients in the SEER database diagnosed with
neuroblastoma, 1973–2015.
neuroblastoma, 1973–2015.
Table 2 shows the unadjusted and adjusted hazard ratios for 5-year cause-specific survival in
the study sample. The final adjusted model included age, gender, ethnicity, stage, site, and year of
diagnosis. These covariates were identified as being clinically relevant and were sued in previous
studies as well [8–14]. In addition, they were unequally distributed according to the race (Table 1)
and the survival. After adjusting for these covariates, there were no statistically significant differences
in the hazard of survival for blacks (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.74–1.16) or
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Table 2. Unadjusted and adjusted hazard ratios for 5-year cause-specific survival among patients in
the SEER database diagnosed with neuroblastoma between 1973 and 2015.
Characteristics

Unadjusted
a

HR (95% CI
Race
White
Black
API d

Adjusted
b)

HR (95% CI)

Ref.c
1.04 (0.83–1.30)
1.02 (0.76–1.35)

Ref.
0.93 (0.74–1.16)
1.02 (0.76–1.37)

<1 years
1–4 years
5–17 years

Ref.
6.65 (5.22–8.47)
8.57 (6.49–11.31)

Ref.
5.92 (4.64–7.56)
7.29 (5.51–9.66)

Male
Female

Ref.
0.86 (0.74–1.00)

Ref.
0.89 (0.76–1.04)

Ref.
0.77 (0.58–1.02)

Ref.
1.00 (0.75–1.34)

Ref.
3.63 (1.91–6.88)
13.45 (7.39–24.50)
7.78 (4.24–14.29)

Ref.
3.06 (1.61–5.80)
9.03 (4.94–16.49)
7.32 (3.97–13.51)

Non-Adrenal
Adrenal

Ref.
1.37 (1.18–1.59)

Ref.
1.16 (0.99–1.36)

1973–1999
2000–2004
2005–2015

Ref.
0.51 (0.40–0.65)
0.39 (0.31–0.48)

Ref.
0.46 (0.36–0.59)
0.33 (0.26–0.41)

Age

Sex

Ethnicity
Non-Hispanic
Hispanic
Stage
Localized
Regional
Distant
Unstaged/Unknown
Site

Year

a

Hazard Ratio; b Confidence Interval; c Reference Group; d Asian Pacific Islander.

Figure 2 displays the adjusted hazard ratios of race, ethnicity, sex, type of cancer and year of
diagnosis for 5-year cause-specific survival among patients in the SEER database diagnosed with
neuroblastoma between 1973 and 2015. Patients diagnosed between 2000–2004 and 2006–2015 had
increased survival compared with patients diagnosed during 1973–1999.
Int. J. Environ. Res. Public Health 2020, 17, x
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Black vs White
API vs White
Women vs Men
Hispanic vs Non-Hispanic
Adrenal vs Non-Adrenal
2000-2004 vs 1973-1999
2005-2015 vs 1973-1999

0

0.5

1

1.5

2

Hazard ratio
Figure 2. Forest plot of the adjusted hazard ratios of race, ethnicity, sex, type of cancer, and year of

Figure 2. Forest
plotfor
of 5-year
the adjusted
hazard
ratios
ofpatients
race, ethnicity,
typediagnosed
of cancer,
diagnosis
cause-specific
survival
among
in the SEERsex,
database
withand year of
between 1973 and
2015. among patients in the SEER database diagnosed with
diagnosis forneuroblastoma
5-year cause-specific
survival
neuroblastoma between 1973 and 2015.
4. Discussion

The results showed no association between race and survival among pediatrics patients diagnosed
with neuroblastoma, survival improved among all patients diagnosed after the year 2000.
Our results update and expand the results reported in previous studies using SEER [10,11,18]. A
study analyzing survival between black and white patients with childhood cancer from 1992 to 2000
and from 2001 to 2007 revealed that despite significantly improved treatment outcomes, black patients
had significantly poorer rates of survival in both study periods compared with white patients [11].
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4. Discussion
The results showed no association between race and survival among pediatrics patients diagnosed
with neuroblastoma, survival improved among all patients diagnosed after the year 2000.
Our results update and expand the results reported in previous studies using SEER [10,11,18].
A study analyzing survival between black and white patients with childhood cancer from 1992 to 2000
and from 2001 to 2007 revealed that despite significantly improved treatment outcomes, black patients
had significantly poorer rates of survival in both study periods compared with white patients [11].
Moreover, Kehm et al. found that black neuroblastoma patients exhibited 38% higher risk of mortality
compared with white patients after adjusting for age, sex, and stage of diagnosis [18]. However,
the emphasis of their paper was more on the role of socioeconomic status on outcomes and highlighted
the mediating fore of socioeconomic status when looking at race. Finally, research comparing the
survival rates by race among children with common extracranial solid tumors between 1985 and
2005 reported that black children had a 31% higher risk of death compared with white children [10].
Studies that used other databases than SEER reported inconsistent results with regard to an association
between race and survival in children with neuroblastoma [8,12–14]. In the early 1970s, DiNicola et al.
compared the survival rates of 30 white and 15 black children with neuroblastoma treated at the
Children’s Hospital National Medical Center in Washington DC [14]. They did not reveal a statistically
significant difference between the white and black children regarding median duration of survival
or percentage of long-term survivors [14]. Henderson et al. showed a significantly increased risk
of death from neuroblastoma in blacks compared to whites, before adjustment for risk groups [8].
After adjustment, overall survival did not differ between white and black patients. However,
among patients who remained event-free for 2 years or longer, survival was worse in blacks compared
with whites (HR 1.5, 95% CI 1.0–2.3) [8]. Also, a US cohort study including 2709 patients revealed
that African genomic ancestry was associated with a 40% lower event-free survival demonstrating
that common genetic variation influences neuroblastoma phenotype and contributes to the ethnic
disparities in survival observed [13]. Finally, a recent study in patients diagnosed with neuroblastoma
between 1986 and 2012 using data from the Therapeutically Applicable Research to Generate Effective
Treatments initiative did not find any statistically significant differences in survival between black and
white patients [12].
Several explanations for our observations can be elucidated. Our data from the SEER database
included more recent patient cases, particularly from 2010 onwards. Previous literature had access to
data as recent as 2009. This, combined with continued changes in treatment protocols for neuroblastoma
in 2000 and 2005, may have led to a narrowing of the racial disparity based on survival [16].
This hypothesis is supported by our findings of significantly increased survival among all patients
from the year 2000 on. The improved survival could have been the result of changes in neuroblastoma
treatment protocols. Before the year 2000, the standard of care included high-dose chemotherapy
(HDT) with stem-cell transplantation. In the latter time period, immunotherapy and cytokines plus
isotretinoin were added to the treatment regimen [16]. Thus, these changes in treatment regimens could
have led to better outcomes. Additionally, improved access to healthcare among patients of all races
may have also played a role in the difference of this study with those using data from earlier years.
Our analyses also showed that an adrenal source of neuroblastoma was not significantly associated
with survival when compared to a non-adrenal source, which was not expected. Previous literature
has shown that an adrenal site is associated with worse survival than a non-adrenal site, but our
results were not consistent with that [19]. A study of children younger than age 21 years diagnosed
with NB or ganglioneuroblastoma between 1990 and 2002 and with known primary site were
identified from the International Neuroblastoma Risk Group database has shown that patients
with primary adrenal tumors have a statistically significant worse event free survival and overall
survival compared to non-adrenal sites (HR 1.17; CI 1.05–1.29) even after adjustment for age,
MYCN proto-oncogene status, and stage [20]. Possible reasons for the varying results could have
been due to the different categorization and use of patient characteristics, neuroblastoma sites,
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time periods, and the use of different databases. For example, Vo et al. used patients up to the age
of 21, included patients with ganglioneuroblastoma, investigated data from 1990 to 2002, and used
patients enrolled in the International Society of Pediatric Oncology Europe Neuroblastoma group,
Localized Neuroblastoma European Study, a North American Children’s Oncology group study,
and trials from other countries [20]. In our study, we categorized our neuroblastoma sites as follows:
adrenal, mediastinum, ANS, retroperitoneum, connective tissue, and CNS, before simplifying it
to adrenal vs. non-adrenal neuroblastoma. Other studies chose to organize by gross anatomic
classification. For example, Vo et al. used adrenal, abdominal/retroperitoneal, neck, thoracic, pelvic,
and other sites [20]. Furthermore, increased stage and distant site are often useful predictors of
worsening survival among cancer patients.
Some limitations should be considered. The SEER database only records information from the
following geographic locations: Connecticut, New Mexico, Iowa, California, Kentucky, New York, Utah,
Georgia, Hawaii, Massachusetts, Wisconsin, Detroit, and Louisiana [10]. There is also incompleteness
in patient information with respect to treatment course, family income, or family history which limits
the adjustment of these variable [17]. In addition, misclassification of race is possible, and it could
lead to underestimation of differences in survival between blacks and whites. A similar limitation
was reported with regards to the over-classification of Hispanic patients by the SEER database for
patients between 1975 and 1999, possibly underestimating differences in survival among Hispanic and
Non-Hispanic pediatric patients with cancer [8,21]. Moreover, insurance status information was not
available prior to 2007 and previous studies have shown that black children with acute lymphocytic
leukemia, who had worse outcomes in survival were less likely have private insurance and more
likely to have public insurance [4]. Furthermore, we did not have access to information related to
variables such as socioeconomic status and education. Social determinants may be the underlying
factors in racial disparities of survival in neuroblastoma patients, and future research may study
these factors in more detail. We are also aware that according to international consensus an age
cut-off of 1-year-old is not standard and that 1.5 years should be considered [22]. However, age is
collected in SEER as a discrete variable measured in full years. Thus, it was not possible to create
age a cut-off value of 1.5 years-of-age. In order to find out whether this altered our results, we run
additional analysis excluding children below the age of 1 (n = 877). The HRs and 95% CI remained
statistically non-significant. Lastly, there are some latent biological factors beyond those available in
SEER that are known to affect survival in neuroblastoma patients and may be potentially confounded
with race, such as MYCN, ploidy, and tumor histology, among others. Randomized clinical trials are
better study designs to control for confounders than observational studies. However, because of the
nature of our exposure a randomized clinical trial is not applicable for our research question. Thus,
best scientific evidence needs to be derived from future cohort studies that may control for most of the
above-mentioned confounders we did not have available.
5. Conclusions
In conclusion, this study found no evidence of an association between race and survival among
pediatric patients diagnosed with neuroblastoma. Future studies should have a closer look at what other
factors, socioeconomic or otherwise, may influence survival among this patient population. In our analysis,
insurance was used as a surrogate for socioeconomic status when assessing its influence on the relationship
between race and survival. The fact that the entire pediatric population had at least some form of insurance
and that there was no statistical significance in mortality based on the type of insurance serves as a
compelling reason to employ universal healthcare. In addition, research that can address and fix the
limitations of ours and previous studies in order to compare results and make a more definitive claim
about the association between race and survival should still be pursued. Finally, the change in standard of
treatment after 2000 showed a statistically significant decrease in hazard ratio. Thus, survival improved
among all patients treated during 2000–2004 and 2005–2015 compared with those treated before the
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year 2000, leading to a narrowing of the racial disparity based on survival. Improvements in treatment
specific protocols should be pursued for all patients to benefit overall survival outcomes.
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